Karyopharm Therapeutics Inc. (KPTI) financial statements (2021 and earlier)

Company profile

Business Address 85 WELLS AVENUE
NEWTON, MA 02459
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments249262328146130176206
Cash and cash equivalents86129118695058151
Short-term investments163133210778011755
Restricted cash and investments21 0   
Receivables138     
Inventory, net of allowances, customer advances and progress billings30     
Inventory30     
Other undisclosed current assets9762222
Total current assets:277279335148132178208
Noncurrent Assets
Operating lease, right-of-use asset911
Property, plant and equipment2342333
Long-term investments and receivables24222945349
Long-term investments24222945349
Restricted cash and investments1110000
Other noncurrent assets      1
Total noncurrent assets:3716732493813
TOTAL ASSETS:313295341180180215220
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities57423727161514
Accounts payable4146546
Accrued liabilities5341322111116
Employee-related liabilities      2
Deferred revenue02
Debt 2     
Deferred rent credit  0
Deferred revenue and credits22000
Other liabilities1100000
Other undisclosed current liabilities2 9   (2)
Total current liabilities:60464749161512
Noncurrent Liabilities
Long-term debt and lease obligation129123103    
Long-term debt, excluding current maturities118110103    
Operating lease, liability1113
Liabilities, other than long-term debt 241221
Deferred revenue and credits1221
Deferred revenue 2
Deferred rent credit  4
Other undisclosed noncurrent liabilities62745    
Total noncurrent liabilities:2021991111221
Total liabilities:26324515851181714
Stockholders' equity
Stockholders' equity attributable to parent5150183129162198207
Common stock0000000
Additional paid in capital1,120923857625529455345
Accumulated other comprehensive income (loss)1(0)(0)(0)(0)(0)(0)
Accumulated deficit(1,070)(873)(674)(495)(366)(257)(138)
Total stockholders' equity:5150183129162198207
TOTAL LIABILITIES AND EQUITY:313295341180180215220

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues10841302000
Revenue, net2000
Cost of revenue
(Cost of Goods and Services Sold)
(0)      
Gross profit:10841302000
Operating expenses(280)(230)(210)(132)(111)(119)(76)
Other undisclosed operating income0      
Operating loss:(172)(189)(180)(131)(111)(119)(76)
Nonoperating income (expense)(24)(10)22110
Investment income, nonoperating3542110
Other nonoperating income (expense)0(0)(0)(0)0(0)0
Interest and debt expense(27)(16)(2)   (0)
Other undisclosed income from continuing operations before equity method investments, income taxes27162    
Loss from continuing operations before income taxes:(196)(200)(178)(129)(109)(118)(76)
Income tax expense (benefit)(0)(0)(0)(0)(0) 76
Net income (loss):(196)(200)(178)(129)(110)(118)1
Other undisclosed net loss attributable to parent      (76)
Net loss available to common stockholders, diluted:(196)(200)(178)(129)(110)(118)(76)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(196)(200)(178)(129)(110)(118)1
Comprehensive income (loss):(196)(200)(178)(129)(110)(118)1
Other undisclosed comprehensive income (loss), net of tax, attributable to parent10(0)00(0)(76)
Comprehensive loss, net of tax, attributable to parent:(196)(199)(178)(129)(110)(118)(76)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: